Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Regulatory News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

Share Price is delayed by 15 minutes
Get Live Data
46.00    0.00 (0.00%)
Bid:
45.00
Ask:
47.00
Spread: 2.00 (4.444%)
Market Cap: £91.78m
FARN Live PriceLast checked at - London Stock Exchange

Intraday Faron Pharmaceuticals Share Chart

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

16 Apr 2026 15:00

Faron Pharmaceuticals Ltd | Company announcement | April 16, 2026 at 18:00:00 EEST

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:Faron Pharmaceuticals Ltd
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuerx
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rightsx
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rightsx
Other (please specify) iii: Dividend payments in kind.
3. Details of person subject to the notification obligation iv
NameTimo Syrj¤l¤
City and country of registered office (if applicable)Monaco
4. Full name of shareholder(s) (if different from 3.) v
NameAcme Investments SPF Sarl
City and country of registered office (if applicable)Luxembourg
5. Date on which the threshold was crossed or reached vi:15.4.2026
6. Date on which issuer notified (DD/MM/YYYY):16.4.2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)Total of both in % (8.A + 8.B)Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached7.77%15.509.433
Position of previous notification (ifapplicable)12.69%14.697.112
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type ofsharesISIN code (if possible)Number of voting rights ix% of voting rights
Direct(DTR5.1)Indirect(DTR5.2.1)Direct(DTR5.1)Indirect(DTR5.2.1)
FI40001533095.949.3209.560.1132.98%4.79%
SUBTOTAL 8. A15.509.4337.77%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrumentExpirationdate xExercise/ Conversion Period xiNumber of voting rights that may be acquired if the instrument isexercised/converted.% of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrumentExpirationdate xExercise/ Conversion Period xiPhysical or cashSettlement xiiNumber of voting rights% of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark theapplicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xivX
Name xv% of voting rights if it equals or is higher than the notifiable threshold% of voting rights through financial instruments if it equals or is higher than the notifiable thresholdTotal of both if it equals or is higher than the notifiable threshold
Timo Syrj¤l¤ (Direct)2.98%2.98%
Acme Investments SPF Sarl (Indirect)4.79%4.79%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information Faron share issue during April 2026
Place of completionMonaco
Date of completion16.4.2026
Date   Source Headline
6th Feb 20257:00 amMFNResults of the Significantly Oversubscribed Placing
5th Feb 20254:30 pmMFNProposed Issue and Placing
5th Feb 20254:30 pmRNSProposed Issue and Placing
31st Jan 20257:00 amRNS-RFinal Patient Identified for BEXMAB Phase II Study
13th Dec 20247:00 amRNSFaron’s Financial Calendar for 2025
27th Nov 20247:00 amRNSPositive Phase 2 Interim Results from BEXMAB Trial
5th Nov 20247:00 amRNSShareholders’ Nomination Board
22nd Oct 20247:00 amRNSFaron’s Capital Markets Day 2024
30th Aug 20247:00 amRNSGrant of options
27th Aug 20247:00 amRNSFaron 2024 Half-Year Financial Results
27th Aug 20247:00 amRNSFDA Grants Fast Track Designation for Bexmarilimab
20th Aug 20247:00 amRNSNotice of Half-Year Financial Results
8th Aug 20247:00 amRNSAppointment of Chief Financial Officer
7th Aug 202410:00 amRNSGrant of options
6th Aug 20248:30 amRNSFaron Appoints Dr. Petri Bono as new CMO
11th Jul 20247:00 amRNSFaron Announces Positive FDA Feedback
25th Jun 20242:00 pmRNSUpdate on settlement
25th Jun 202410:30 amRNSHolding(s) in Company - Replacement
24th Jun 202412:45 pmRNSHolding(s) in Company
24th Jun 202412:45 pmRNSHolding(s) in Company
24th Jun 202412:45 pmRNSHolding(s) in Company
24th Jun 202412:45 pmRNSHolding(s) in Company
20th Jun 20241:00 pmRNSNew shares registered with Finnish Trade Register
20th Jun 20247:00 amRNSFully subscribed EUR 30.7 million share offering
5th Jun 20248:00 amRNSProposed REX Retail Offer
4th Jun 20247:00 amRNSFaron commences a share offering
20th May 20247:00 amRNSInitial positive data from Phase 2 of BEXMAB
17th May 20244:00 pmRNSIssuance of warrants
16th May 20247:05 amRNSFounders named European Inventor Award finalists
13th May 20247:00 amRNSReplacement – Board Change
30th Apr 20242:00 pmRNSUpdate on financial status
30th Apr 20241:00 pmRNSBoard Change
16th Apr 20247:00 amRNSFaron confirms plans under new leadership
15th Apr 20247:00 amRNSAppointment of Chief Financial Officer
8th Apr 20247:10 amRNSApproval of Warrant Terms and Conditions
8th Apr 20247:05 amRNSDecisions of the Board of Directors
8th Apr 20247:00 amRNSAppointment of Chief Executive Officer
5th Apr 202412:00 pmRNSResults of the Annual General Meeting
4th Apr 20247:00 amRNSAnnouncement of Placing
28th Mar 20247:00 amRNSIssue of Warrants to IPF Funding Update
26th Mar 202410:00 amRNSFaron´s Annual Report 2023
18th Mar 20247:00 amRNSAdditional Positive Data from Phase 1 of BEXMAB
14th Mar 20247:00 amRNSFaron to Host BEXMAB Webcast
13th Mar 20242:00 pmRNSNotice of Annual General Meeting 2024
13th Mar 20247:00 amRNSFinancial Statement January 1 to December 31 2023
4th Mar 20247:00 amRNSBinding commitments for convertible loans
28th Feb 20244:00 pmRNSReplacement - Update to 2024 Financial Calendar
27th Feb 20246:00 pmRNSUpdate to Faron’s Financial Calendar for 2024
21st Feb 20242:00 pmRNSContinued Negotiations Regarding Events of Default
19th Feb 202410:30 amRNSEvents of Default

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.